On Survival and Responding to Change

I recently stumbled across the following sentence: It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change.” The line is attributed to Charles Darwin and struck me as pertaining to our current situation as busy providers in a health care system which seems to change at (too) many levels simultaneously and at a pace that makes one wonder whether there is still a system – if there ever was one in the first place.

Working hard as a provider caring for patients in the middle of all these changes makes one feel powerless, generates anger and frustration which, in turn, carry the danger of leading to apathy and disengagement, potentially ending in burn-out. There are at least two other options: to leave or to speak up. While leaving for greener pastures, if there are any, may be a solution for an individual, it does not help those who cannot afford to quit for whatever reason and have to stay behind. The latter and the system as a whole need those who speak up; not for their own self-interests, but in order to improve the greater good and make our (health care) world a better place. This requires not only resilience and courage, but also the willingness to take on responsibility, and the ability to choose the right moment for the right message targeted at the right audience, i.e. patience paired with persistence; not an easy task.

And then – and that’s where Darwin comes into play – we, as individuals, need to be willing to make an effort and adapt to an ever changing environment. Not just trying to find the hair in the soup, but tasting the flavor; not just getting stuck with pointing out the problems, but finding solutions; not always comparing with the past, but creating the future. This needs optimism, looking at the glass half full, always attempting to find ways to fill it up even higher. It also requires to listen and observe before judging, to swallow and reflect before talking, and to stay humble, always keeping the greater good in mind.  If we accomplish this, we will not only make our health care world a better working place, but also survive into the future to provide the best possible care to our patients.

Let’s do it, together we can!

Nick Anthonisen Award of Excellence

 

The Nick Anthonisen Award of Excellence was created in 2015 thanks to a very generous sponsorship from Astra Zeneca.

This is one of five awards that Astra Zeneca funds across Western Canada with the goal of creating a network among Respirologists in Western Canada.

The award consists of a plaque as well as a one thousand dollar monetary award to be used towards an academic pursuit of the recipient.

Dr. M. Ainslie, Dr. N. Porhownik

Each year a member of the adult respiratory division who contributes significantly to the academic mission of the division is selected by the selection committee. This year the selection committee has chosen a member who contributes to the adult respiratory division’s educational mandate and is the current Program Director – Dr. Nancy Porhownik.

Dr. Porhownik has a busy clinical load with areas of expertise in sleep medicine, cystic fibrosis, and lung transplant.  She is currently the Medical Director of the Lung Transplant Program, and under her guidance our program has become affiliated with the Edmonton Transplant program. This affiliation has resulted in a significant increase in lung transplant recipients in Manitoba. She is the current Program Director and is currently overseeing and guiding the program towards implementation of CBD – which will be the biggest change in post grad education since the introduction of CANmeds. Thanks to Nancy’s leadership the program will be able to smoothly introduce CBD.

Nancy Porhownik works tirelessly for her trainees and for the program and is a role model not only with respect to clinical care, but also to her work/ life balance.

Please join us in congratulating Nancy Porhownik on being this year’s recipient of the Nick Anthonisen Award of Excellence.

Interventional Cardiology Fellowship

We are delighted to announce that the Section of Cardiology’s application for AFC (Area of Focused Competency) for accreditation for the Interventional Cardiology fellowship has been successful and has been approved and accredited by the RCPSC. This will help the Section of Cardiology attract strong future candidates and validates the strength of  the training program.

Clinical Fellowships allow trainees to obtain further skills and knowledge in various subspecialties. Traditionally there has been no accreditation for this training. In recent years, the Royal College started the AFC (area of focused competency) diploma program to allow training programs in recognized disciplines to become accredited and allow trainees to obtain Royal College diplomas.

We would also like to emphasize that this is the first accredited and approved AFC program in the PGME department at the Max Rady          College of Medicine at the University of Manitoba!


Congratulations are extended to  Dr. Basem Elbarouni, Program Director for Interventional Cardiology, who was the lead for the AFC submission.

CIHR Grant Awarded to N. Mookherjee, PhD

Project Title:   Innate Defence Regulator (IDR) peptides: Regulatory Mechanisms in the Control of Asthma”

Term: 5 years              Approved total funding amount:   $661,725.

Principal Investigator (PI): 

Neeloffer Mookherjee PhD,  Section of Proteomics & Systems Biology

    Abstract:   Asthma is the most common chronic respiratory disease, characterized by inflammation in the lungs and narrowing of the airways, which makes it difficult to breathe. Nearly 3 million Canadians suffer from asthma. The direct and indirect cost related to asthma in Canada is around $2.2 billion annually. Nearly 10% of patients do not respond to available steroid therapies and have severe uncontrolled asthma. These patients represent the major burden of asthma and associated healthcare costs. Moreover, commonly used steroid therapies can increase the risk of lung infections, which results in worsening of asthma. Therefore, there is an urgent need to develop new therapies that can control asthma, without compromising a patient’s ability to resolve infections. Dr. Mookherjee’s study focuses on new molecules known as innate defence regulator (IDR) peptides, which are designed from natural molecules that play a critical role in the immune response. IDR peptides can control both inflammation and infection in the lung, with the potential to overcome side effects associated with current therapies. We have shown that IDR peptides improve breathing capacity in an animal model of asthma, and can control cellular processes linked to steroid unresponsiveness. This project is aimed at the development of IDR peptides as a new therapy for asthma. This project will identify the changes that occur in lung cells after they are treated with IDR peptides. We will also study the biological effects of IDR peptides in the control of lung inflammation and fibrosis, in a mouse model of asthma. The results from these studies will allow us to identify new drug targets with the potential to alleviate unresponsiveness to steroid therapies, a condition for which there is currently no effective treatment. This project will directly support the development of a new IDR peptide-based therapy for asthma, which will have the added benefit of countering steroid-refractory asthma and controlling lung infections

    Congratulations Dr. Mookerjee!